DMRA 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• Both DMR-001 and DMR-002 were designed to have an extended half-life supporting convenient once-monthly subcutaneous administration.

• Beginning with our lead asset DMR-001, we are developing these candidates for the treatment of essential thrombocythemia (“ET”), an MPN associated with the overproduction of platelets, and myelofibrosis (“MF”), an MPN involving the overproliferation of blood cells and deposition of fibrous material …

• MPNs are caused by excessive proliferation of myeloid cells. In some patients, including ET patients, MPNs are considered chronic diseases that lead to significant decreases in quality of life. MPNs also include MF, which is associated with poor prognosis and increased mortality. One feature that ma…

• We recently initiated our Phase 1/1b trial of DMR-001 in ET and MF patients, and in parallel to advancing DMR-001, we plan to make our first regulatory submission for DMR-002 in the second half of 2026 and for DMR-003 in 2027.

• DMR-001 is a monoclonal antibody that targets mutations in CALR across both Type 1 and non-Type 1 CALR mutations, including Type 2 mutations. CALR mutations are the drivers of about a quarter of all cases of ET, a disease with a prevalence in the United States of about 140,000 patients. ET is charac…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• Beginning with our lead asset DMR-001, we are developing these candidates for the treatment of essential thrombocythemia (“ET”), an MPN associated with the overproduction of platelets, and myelofibrosis (“MF”), an MPN involving the overproliferation of blood cells and deposition of fibrous material …

• MPNs are caused by excessive proliferation of myeloid cells. In some patients, including ET patients, MPNs are considered chronic diseases that lead to significant decreases in quality of life. MPNs also include MF, which is associated with poor prognosis and increased mortality. One feature that ma…

• DMR-001 is a monoclonal antibody that targets mutations in CALR, including the two major forms of CALR mutations referred to as Type 1 and Type 2 mutCALR. CALR mutations are the drivers of about a quarter of all cases of ET, a disease with a prevalence in the United States of about 140,000 patients.…

• We believe that DMR-001 has the potential to become a best-in-class anti-mutCALR therapy due to two differentiating features compared to marketed therapies and therapies in development, including INCA033989. First, our preclinical studies demonstrated that DMR-001 is a more potent inhibitor of mutCA…

• The expected combination of increased clinical activity and longer half-life is predicted to enable the delivery of sufficient amounts of DMR-001 via subcutaneous injection to match and potentially exceed the reported efficacy of INCA033989 that was intravenously administered in Incyte Corporation’s…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• The market price of our Ordinary Shares has been and is expected to continue to be volatile.

• If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.

• Conflicts of interest may arise between us and Paragon or us and Fairmount.

• recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, patient registration for clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies complementary to, or necessary for, o…

• candidates, before we receive regulatory approval from the FDA and comparable foreign regulatory authorities, and we may never receive such regulatory approvals.

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• The market price of our Common Stock has been and is expected to continue to be volatile.

• If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.

• Conflicts of interest may arise between us and Paragon or us and Fairmount.

• The success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights, potential threats fro…

• distribution and sales efforts of any current or future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of these product candidates, even if approved. If we are not successful in obtaining regulatory approval and commercializing DMR-001,…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• On August 6, 2026, our board of directors appointed Andrew Cheng, M.D., Ph.D. as a Class III director effective as of August 12, 2026 (the “Effective Date”). In connection with his appointment, Dr. Cheng was appointed as a member of the Compensation Committee of the board of directors.

• Andrew Cheng, M.D., Ph.D. (Age 59). Dr. Cheng has served as President, Chief Executive Officer and Chairman of the Board of Avere Therapeutics, a biotechnology company, since 2026. He previously served as President and Chief Executive Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), a biotechnolo…

• In connection with his appointment as a director, Dr. Cheng will receive a cash retainer and an initial grant of equity awards in accordance with the Company’s non-employee director cash and equity compensation program. The equity award will be an option to purchase the lesser of (i) 40,000 Ordinary…

• In connection with his appointment as a director, Dr. Cheng will enter into our standard form of indemnification agreement for directors, a copy which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q.

• There are no family relationships between Dr. Cheng and any of our executive officers or directors. There are no arrangements or understandings between Dr. Cheng and any other person pursuant to which he was appointed as one of our directors. Dr. Cheng is not a party to any transaction required to b…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• During the three months ended March 31, 2026, none of the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5…